The effects of sitaglibtin, glutazone and other glucose lowering drugs on inflammatory and coagulative factors and lipid profile in type 2 diabetes patients

Phase 3

Recruiting

• Conditions: Type 2 diabetes.; Type 2 diabetes mellitus with hyperosmolarity

• Registration Number: IRCT20130610013612N9
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 July 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Age 45-55 years
HbA1C is more than 7 in less than 8.
BMI is greater than 25 and less than 30.

Exclusion Criteria

Having any cardiovascular, inflammatory, autoimmune disease
Taking warfarin
Presence of infection

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
High-Sensitivity C-Reactive Protein. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;HDL Cholesterol. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Fibrogen. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.

Secondary Outcome Measures

Name	Time	Method
Fast blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Cholestrol. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Triglyceride. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Weigh.